WHO ICTRP trial
Median effective plasma concentration of remifentanil inhibiting cardiovascular…
ChiCTR-OOC-16010257 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-OOC-16010257 |
|---|---|
| Public title | Median effective plasma concentration of remifentanil inhibiting cardiovascular response to CO2 pneumoperitoneum stimulus when combined with propofol in patients undergoing laparoscopic gynaecological surgery |
| Scientific title | Median effective plasma concentration of remifentanil inhibiting cardiovascular response to CO2 pneumoperitoneum stimulus when combined with propofol in patients undergoing laparoscopic gynaecological surgery |
| Primary sponsor | Southern District of Anhui Provincial Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | Other |
| Countries | China |
| Conditions | Laparoscopic gynaecological surgery |
| Interventions | Study group:propofol and remifentanil |
| Registration date | Dec 26, 2016 |
| Target size | Study group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: